ArticleGenes2022
Polymorphisms in
Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- Article
- Association of HLA-B gene polymorphism and blood groups with COVID-19 susceptibility and severity.Scientific reports · 2025Article
- Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course.Journal of personalized medicine · 2025Article
- Article
- Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables.Scientific reports · 2024Article
- Identification of common genes of rhinovirus single/double‑stranded RNA‑induced asthma deterioration by bioinformatics analysis.Experimental and therapeutic medicine · 2024Article
- Gene Variants of the OAS/RNase L Pathway and Their Association with Severity of Symptoms and Outcome of SARS-CoV-2 Infection.Journal of personalized medicine · 2024Article
- Type I interferon pathway genetic variants in severe COVID-19.Virus research · 2024Review
- Genomic insight into COVID-19 severity in MAFLD patients: a single-center prospective cohort study.Frontiers in genetics · 2024Article
- Evaluation of IFNAR2 and TYK2 transcripts' prognostic role in COVID-19 patients: a retrospective study.Frontiers in cellular and infection microbiology · 2024Article
- Association of IFNAR2 and TYK2 with COVID-19 pathology: current and future.Frontiers in immunology · 2024Article
- Participation of Single-Nucleotide Variants inPathogens (Basel, Switzerland) · 2023Review
- The Relationship between COVID-19 Severity in Children and Immunoregulatory Gene Polymorphism.Viruses · 2023Article
- TheInternational journal of molecular sciences · 2023Article
- Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis.Viruses · 2023Review
- COVID-19 annual update: a narrative review.Human genomics · 2023Review
- Association of IFIH1 and DDX58 genes polymorphism with susceptibility to COVID-19.Medical microbiology and immunology · 2023Article
- Impact of COVID-19 on Cardiovascular Disease.Viruses · 2023Review
- TYK2, IFITM3, IFNAR2 and OAS3 single-nucleotide polymorphisms among severe COVID-19 ICU patients in Morocco.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although advanced age, male sex, and some comorbidities impact the clinical course of COVID-19, these factors only partially explain the inter-individual variability in disease severity. Some studies have shown that genetic polymorphisms contribute to COVID-19 severity; however, the results are inconclusive. Thus, we investigated the association between polymorphisms in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.